Article By:
ChinaBio® Today
Saturday, November 4, 2023 3:00 PM EDT
Jiangsu Hengrui Pharma out-licensed global rights for its next-gen PARP1 inhibitor to Germany’s Merck KGaA for a $170 million upfront payment and up to $1.5 billion in milestones. Merck will have rights to manufacture and commercialize the drug.
Another Bad Day For Stocks
I like $BLRX. What was the Gamida cell news that I missed?